Raffaele Migliore
2 presentations
-
W37. LUMATEPERONE 42 MG IN MAJOR DEPRESSIVE DISORDER: DEMOGRAPHIC AND CLINICAL SUBGROUPS EFFICACY ANALYSIS IN A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED TRIAL
-
T42. REMISSION WITH LUMATEPERONE 42 MG ADJUNCTIVE TO ANTIDEPRESSANT THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: ANALYSIS OF SHORT-TERM AND LONG-TERM TRIALS